Predictors of deteriorating cerebral infarct: Role of inflammatory mechanisms. Would its early treatment be useful?

Cerebrovascular Diseases

Volumn 11, Issue SUPPL. 1, 2001, Pages 40-48

  Castillo, José ^a,b   Leira, Rogelio ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Early deterioration; Inflammatory mechanisms; Progressing stroke

Indexed keywords

CD31 ANTIGEN; EXCITATORY AMINO ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CELL DESTRUCTION; CONFERENCE PAPER; DISEASE COURSE; HEMODYNAMIC MONITORING; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MORBIDITY; MORTALITY; NERVE CELL NECROSIS; PREDICTION; PRIORITY JOURNAL; REPERFUSION; TREATMENT OUTCOME;

CEREBRAL INFARCTION; CYTOKINES; DISEASE PROGRESSION; ENCEPHALITIS; HUMANS; NEUROIMMUNOMODULATION; PREDICTIVE VALUE OF TESTS;

EID: 0035099630     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049124     Document Type: Conference Paper

References (72)

1. Deteriorating ischemic stroke: Risk factors and prognosis
2. Progressing neurological deficit secondary to acute ischemic stroke
3. Progression of ischaemic stroke and excitotoxic amino acids
4. Body temperature and fibrinogen are related to early neurological deterioration in acute ischemic stroke
5. Predictors of neurological deterioration in acute ischemic stroke
6. Neurological deterioration in acute ischemic stroke. Potential predictors and associated factors in the European Cooperative Acute Stroke Study
7. Progressing stroke
8. Deteriorating stroke: Diagnostic criteria, predictors, mechanisms and treatment
9. Effect of blood pressure and diabetes on stroke in progression
10. Rödén-Júllig A Progressing stroke: Epidemiology
11. Characterising the target of acute stroke therapy
12. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
13. Tissue plasminogen activator for acute ischemic stroke
14. Randomised, double-blind, placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australian Acute Study investigators
15. Predictors of stroke outcome
16. Early clinical and radiological predictors of fatal brain swelling in ischemic stroke
17. Conjugate eye deviation: Side, site, and size of the hemispheric lesion
18. Prediction of long-term outcome in the early hours following acute ischemic stoke. Italian Acute Stroke Study Group
19. Comparison of neurological scales and scoring systems for acute stroke prognosis
20. Generalized headache at the onset of ischemic stroke predicts neurological worsening
21. Amino acid transmitters in patients with headache during the acute phase of cerebrovascular ischemic disease
22. Headache and early cranial CT signs of poor outcome in acute ischemic stroke
23. Stroke severity in atrial fibrillation: The Framingham Study
24. The prevention and treatment of medical complications in hospitalized stroke patients
25. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke
26. Mortality and morbidity of acute cerebral infarction related to temperature and basal analytic parameters
27. Body temperature in acute stroke. Relation to stroke severity, infarct size, mortality, and outcome
28. Timing for fever-related brain damage in acute ischemic stroke
29. Is hyperglycemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study
30. The association of hyperglycemia with cerebral edema in stroke
31. Serum glucose and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke
32. Delay in neurological attention and stroke outcome
33. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk
34. Prediction of hemorrhagic complication after thrombolytic therapy for middle cerebral artery occlusion: Value of pre- and post-therapeutic computed tomographic findings and angiographic occlusive site
35. Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts
36. Infartos infratentoriales con deterioro progresivo (abstract)
37. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale before ultraearly thrombolytic therapy
38. Potential mechanisms of worsening
39. Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
40. Early spontaneous improvement and deterioration of ischemic stroke patients. A serial study with transcranial Doppler ultrasonography
41. Cerebrovascular hemodynamics in progressing stroke
42. Intracranial blood flow velocities in acute ischemic stroke
43. Prediction of stroke outcome with echo-planar perfusion- and diffusion-weighted MRI
44. Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemic in dogs
45. Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders
46. Body iron stores and early neurologic deterioration in acute cerebral infarcts
47. Augmentation of nitric oxide, superoxide, and peroxynitrite production during cerebral ischemia and reperfusion in the rat
48. Nitric oxide-related brain damage in acute ischemic stroke
49. Peroxynitrite formation in focal cerebral ischemia-reperfusion in rats occurs predominantly in the peri-infarct region
50. The role of inflammation after acute stroke. Utility of pursuing anti-adhesion molecule therapy
51. Inflammatory reactions at the blood-endothelial interface in acute stroke
52. Tumor necrosis factor-alpha expression in ischemic neurons
53. Interleukin-6 is a centrally acting endogenous pyrogen in the rat
54. Leukocyte endothelial interactions and regulation of leukocyte migration
55. Endothelial adhesion molecules and their role in inflammation
56. Calcium-related damage in ischemia
57. Viability thresholds and the penumbra of focal ischemia
58. Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbrae region following middle cerebral artery occlusion in the rat: Correlation with histopathology
59. Early prediction of stroke severity. Role of the erythrocyte sedimentation rate
60. C-reactive protein and outcome after ischemic stroke
61. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke
62. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: Kinetics of secretion and relation to the extent of brain damage and outcome of disease
63. Cytokine-induced inflammation and long-term stroke functional outcome
64. Early intrathecal production of interleukin-6 predicts the volume of brain lesion in stroke
65. Serial measurement of interleukin-6, transforming growth factor- and S-100 protein in patients with acute stroke
66. Increased cytokine release from peripheral blood cells after acute stroke
67. Intrathecal release of pro- and anti-inflammatory cytokines during stroke
68. Proinflammatory cytokines and early stroke progression
69. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat
70. Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy
71. Anti-inflammatory cytokines in progressing ischemic stroke
72. Heparin blunts inflammation more effectively than aspirin in acute ischemic stroke. Clinical implications